Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01188603 |
Recruitment Status
:
Completed
First Posted
: August 25, 2010
Results First Posted
: April 10, 2012
Last Update Posted
: May 21, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sexual Dysfunctions, Psychological | Drug: flibanserin 100 mg dose every evening | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 24 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Evaluation of Single Dose and Steady State Pharmacokinetics of Flibanserin Postmenopausal Women With Hypoactive Sexual Desire Disorder |
Study Start Date : | July 2010 |
Actual Primary Completion Date : | October 2010 |
Actual Study Completion Date : | October 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: flibanserin
flibanserin 100 mg dose every evening
|
Drug: flibanserin 100 mg dose every evening
all subjects receive flibanserin
|
- Flibanserin: Area Under the Curve; AUC_0-∞ [ Time Frame: 8 days ]Geometric mean of the AUC_0-∞ of Flibanserin
- Flibanserin: AUC τ,ss [ Time Frame: 8 days ]Geometric mean of the AUC τ,ss of Flibanserin
- Flibanserin: Cmax (Peak Concentration) [ Time Frame: 8 days ]Geometric mean of the Cmax of Flibanserin
- Flibanserin: Cmax,ss [ Time Frame: 8 days ]Geometric mean of the Cmax,ss of Flibanserin
- Flibanserin: Tmax,ss [ Time Frame: 8 days ]Median of the tmax,ss of Flibanserin

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Patients must be in a stable, monogamous heterosexual relationship for at least one year.
- Patients must have a primary diagnosis of Hypoactive Sexual Desire Disorder for at least six months.
- Patients must be naturally postmenopausal women of any age with at least one ovary.
- Patients may participate whether or not they are currently taking systemic hormone therapy provided the therapy was not prescribed for treatment of low sexual desire. Hormone therapy must be at a stable dose for at least six months.
Exclusion criteria:
- Patients with a history of drug dependence or abuse within the past twelve months.
- Patients who have been previously treated with flibanserin.
- Patients who have sexual dysfunctions other than Hypoactive Sexual Desire Disorder, such as: Sexual Aversion Disorder, Substance-Induced Sexual Dysfunction, Dyspareunia, Vaginismus, Gender Identity Disorder,Paraphilia, or Sexual Dysfunction due to a general medical condition.
- Patients who indicate that their sexual partner has inadequately treated organic or psychosexual dysfunction that could interfere with a patients response to treatment.
- Patients whose sexual function was impaired, in the investigators opinion, by abdominal or vaginal hysterectomy, oophorectomy or any other pelvic, vaginal, or urologic surgery.
- Patients with pelvic pain, pelvic inflammatory disease, endometriosis, urinary tract or vaginal infection/vaginitis, cervicitis, interstitial cystitis, vulvodynia, symptomatic vaginal atrophy or any other gynecological pathology requiring further evaluation.
- Patients with a history of unexplained vaginal bleeding within the past twelve months.
- Patients with a history of Major Depressive Disorder within six months prior to Screening; ; active suicidal ideation with intent in the past ten years or suicidal behavior at any time.
- Patients with a history of any other psychiatric disorder that could impact sexual function, increase risks to patient safety, or impair patient compliance. Such disorders include but are not limited to bipolar disorder, psychotic disorders, severe anxiety, eating disorders, and antisocial personality disorders.
- Clinically significant electrocardiogram abnormalities at Screening.
- Patients with a history of dementia or other neurodegenerative disease; organic brain disease; stroke; transient ischemic attacks; multiple sclerosis; spinal cord injury; brain surgery; significant brain trauma; peripheral neuropathy; and epilepsy.
- Patients with ongoing hepatic impairment (cirrhosis, hepatic tumor, or other hepatic disease); peptic ulcer within six months prior to Screening; elevated liver enzymes ; inflammatory bowel disease; gastrointestinal bleeding within two months prior to Screening; Patients who have had bariatric surgery for obesity.
- Patients with a history of angina; atherosclerotic cardiovascular disease; congestive heart failure; cardiomyopathy; symptomatic cardiac valve disease; arrhythmia; hypertension.
- Patients with a history of renal failure; known history of chronic glomerulonephritis.
- Patients with a history of chronic obstructive pulmonary disease, chronic bronchitis, or asthma not well controlled with medication taken twice daily or less.
- Patients with a history of gonadotrophic hormone disorders or uncontrolled diabetes mellitus.
- Uncorrected hypothyroidism or hyperthyroidism.
- Patients with a history of uncontrolled glaucoma.
- Patients with known Human Immunodeficiency Virus infection, Acquired Immunodeficiency Syndrome, other clinically significant immunological disorders or auto-immune disorders such as lupus or scleroderma.
- Patients with a history of any cancer within the past ten years, other than non-invasive, previously resected basal cell carcinoma of the skin.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01188603
United States, Florida | |
511.146.01003 Boehringer Ingelheim Investigational Site | |
Orlando, Florida, United States | |
United States, Kansas | |
511.146.01005 Boehringer Ingelheim Investigational Site | |
Wichita, Kansas, United States | |
United States, Michigan | |
511.146.01001 Boehringer Ingelheim Investigational Site | |
Kalamazoo, Michigan, United States | |
United States, Tennessee | |
511.146.01004 Boehringer Ingelheim Investigational Site | |
Knoxville, Tennessee, United States |
Study Chair: | Sprout Pharmaceuticals | Sprout Pharmaceuticals |
Responsible Party: | Sprout Pharmaceuticals, Inc |
ClinicalTrials.gov Identifier: | NCT01188603 History of Changes |
Other Study ID Numbers: |
511.146 |
First Posted: | August 25, 2010 Key Record Dates |
Results First Posted: | April 10, 2012 |
Last Update Posted: | May 21, 2014 |
Last Verified: | May 2014 |
Additional relevant MeSH terms:
Sexual Dysfunctions, Psychological Mental Disorders |